Beta-Blockers in High-Risk Outpatients with Chronic Obstructive Pulmonary Disease are Associated with All-Cause Mortality – The STATUETTE Cohort Study

References

• The Lancet - Global Burden of Disease. Available from: https://www.thelancet.com/gbd. Accessed September 13, 2020.
   Google Scholar
• Maqsood U, Ho TN, Palmer K, et al. Once daily long-acting beta 2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2019;(3). doi:10.1002/14651858
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med. 2002;166(5):675–679. doi:10.1164/rccm.2112096
   PubMed Web of Science ®Google Scholar
• Mccarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;(2). doi:10.1002/14651858.CD003793.pub3
   Web of Science ®Google Scholar
• Sin DD, Paul Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107(11):1514–1519. doi:10.1161/01.CIR.0000056767.69054.B3
   PubMed Web of Science ®Google Scholar
• Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631–639. doi:10.1016/S2213-2600(15)00241-6
   PubMed Web of Science ®Google Scholar
• Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis. 2018;12:1–16. doi:10.1177/1753465817750524
   Web of Science ®Google Scholar
• Andreas S, Anker SD, Scanlon PD, Somers VK. Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest. 2005;128(5):3618–3624. doi:10.1378/chest.128.5.3618
   PubMed Web of Science ®Google Scholar
• Ikeda T, Anisuzzaman ASM, Yoshiki H, et al. Regional quantification of muscarinic acetylcholine receptors and β-adrenoceptors in human airways. Br J Pharmacol. 2012;166(6):1804–1814. doi:10.1111/j.1476-5381.2012.01881.x
   PubMed Web of Science ®Google Scholar
• Rasmussen DB, Bodtger U, Lamberts M, et al. Beta-blocker, aspirin, and statin usage after first-time myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide analysis from 1995 to 2015 in Denmark. Eur Hear J. 2020;6(1):23–31. doi:10.1093/ehjqcco/qcy063
   Web of Science ®Google Scholar
• Sr S, Tm O, Ee S. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005. doi:10.1002/14651858.CD003566.pub2
   Web of Science ®Google Scholar
• Baker JG, Wilcox RG. β-Blockers, heart disease and COPD: current controversies and uncertainties. Thorax. 2017;72(3):271–276. doi:10.1136/thoraxjnl-2016-208412
   PubMed Web of Science ®Google Scholar
• Leitao Filho FS, Choi L, Sin DD. Beta-blockers in chronic obstructive pulmonary disease: the good, the bad and the ugly. Curr Opin Pulm Med. 2021;27(2):125–131. doi:10.1097/MCP.0000000000000748
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Voelker H, Bhatt SP, et al. Metoprolol for the prevention of acute exacerbations of COPD. N Engl J Med. 2019;381(24):2304–2314. doi:10.1056/nejmoa1908142
   PubMed Web of Science ®Google Scholar
• Gulea C, Zakeri R, Alderman V, Morgan A, Ross J, Quint JK. Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison. Respir Res. 2021;22(1):1–14. doi:10.1186/s12931-021-01661-8
   PubMed Web of Science ®Google Scholar
• Damkjær M, Håkansson K, Kallemose T, Ulrik CS, Godtfredsen N. Statins in high-risk chronic obstructive pulmonary disease outpatients: no impact on time to first exacerbation and all-cause mortality – the STATUETTE cohort study. Int J Chron Obstruct Pulmon Dis. 2021;16:579–589. doi:10.2147/COPD.S296472
   PubMed Web of Science ®Google Scholar
• Pedersen CB. The Danish civil registration system. Scand J Public Health. 2011;39(7 Suppl):22–25. doi:10.1177/1403494810387965
   PubMed Web of Science ®Google Scholar
• Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, Sørensen HT, Hallas J, Schmidt M. Data resource profile: the Danish national prescription registry. Int J Epidemiol. 2017;46(3):798. doi:10.1093/ije/dyw213
   PubMed Web of Science ®Google Scholar
• Ingebrigtsen TS, Marott JL, Lange P, Hallas J, Nordestgaard BG, Vestbo J. Medically treated exacerbations in COPD by GOLD 1-4: a valid, robust, and seemingly low-biased definition. Respir Med. 2015;109(12):1562–1568. doi:10.1016/j.rmed.2015.10.015
   PubMed Web of Science ®Google Scholar
• Reilev M, Pottegård A, Lykkegaard J, Søndergaard J, Ingebrigtsen TS, Hallas J. Increased risk of major adverse cardiac events following the onset of acute exacerbations of COPD. Respirology. 2019;24(12):1183–1190. doi:10.1111/resp.13620
   PubMed Web of Science ®Google Scholar
• GOLD guidelines. Available from: https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf. Accessed August 13, 2021.
   Google Scholar
• Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol. 2008;167(4):492–499. doi:10.1093/aje/kwm324
   PubMed Web of Science ®Google Scholar
• van Buuren S, Groothuis-Oudshoorn K. mice: multivariate imputation by chained equations in R. J Stat Softw. 2011;45(3):1–67. doi:10.18637/jss.v045.i03
   Web of Science ®Google Scholar
• Yang YL, Xiang ZJ, Yang JH, Wang WJ, Xu ZC, Xiang RL. Association of β-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis. Eur Heart J. 2021;41(46):4415–4422. doi:10.1093/eurheartj/ehaa793
   Web of Science ®Google Scholar
• Rasmussen DB, Bodtger U, Lamberts M, et al. Beta-blocker use and acute exacerbations of COPD following myocardial infarction: a Danish nationwide cohort study. Thorax. 2020;75(11):928–933. doi:10.1136/thoraxjnl-2019-214206
   PubMed Web of Science ®Google Scholar
• Rutten FH, Zuithoff NPA, Hak E, Grobbee DE, Hoes AW. Β-Blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010;170(10):880–887. doi:10.1001/archinternmed.2010.112
   PubMed Web of Science ®Google Scholar
• Ekström MP, Hermansson AB, Ström KE. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease: a time-dependent analysis. Am J Respir Crit Care Med. 2013;187(7):715–720. doi:10.1164/rccm.201208-1565OC
   PubMed Web of Science ®Google Scholar
• Su TH, Chang SH, Kuo CF, Liu PH, Chan YL. Β-blockers after acute myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide population-based observational study. PLoS One. 2019;14(3):1–14. doi:10.1371/journal.pone.0213187
   Web of Science ®Google Scholar
• Sundh J, Magnuson A, Montgomery S, Andell P, Rindler G, Fröbert O. Beta-blockeRs to patieNts with CHronIc Obstructive puLmonary diseasE (BRONCHIOLE)-Study protocol from a randomized controlled trial. Trials. 2020;21(1):1–8. doi:10.1186/s13063-019-3907-1
   PubMedGoogle Scholar
• Williams B, Mancia G, Spiering W, et al. 2018 practice guidelines for the management of arterial hypertension of the European society of cardiology and the European Society of Hypertension ESC/ESH Task Force for the Management of Arterial Hypertension. Blood Pressure. 2018;36:314–340. doi:10.1097/HJH.0000000000001961
   Web of Science ®Google Scholar
• Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373–498. doi:10.1093/eurheartj/ehaa612
   PubMed Web of Science ®Google Scholar